CRISPR-Cas systems have revolutionized genetic engineering, offering unprecedented precision and efficiency in genome editing.  Recent developments significantly expand its applications and address limitations.  Base editing, a derivative technology, allows for targeted single-base changes without double-stranded DNA breaks, mitigating off-target effects.  Prime editing, a further refinement, expands the range of possible edits, enabling insertions, deletions, and all possible base-to-base conversions.  Beyond gene correction, CRISPR is increasingly employed in gene regulation, utilizing deactivated Cas proteins (dCas) to modulate gene expression.  Furthermore, advancements in delivery methods, including viral vectors and non-viral nanoparticles, are enhancing the efficacy of CRISPR therapies in vivo.  However, challenges persist, including potential off-target effects, ethical concerns regarding germline editing, and the need for improved delivery systems for specific tissues.  Despite these hurdles, the rapid evolution of CRISPR technologies continues to pave the way for transformative advancements in medicine, agriculture, and biotechnology.